RxDoctor Payments Data

Amy Whitsa, PA

Physician Assistant · Salem, ORNPI 1487322921

Payments from drug & device makers

$2,258in general payments, 2019–2025

Across 110 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$516
  • Novo Nordisk$363
  • Lilly USA, LLC$182
  • Amryt Pharma Holdings Ltd$166
  • Medtronic$125
  • Bayer$110
  • plus $797 from 21 others

What the payments were for

  • Food & beverage$2,24699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,258 in reported general payments places this provider in the 90th percentile of 1,756 physician assistant providers in Oregon.

See all physician assistant providers in Oregon

Medicare billing

Part B allowed, 2024
$22,766
Medicare patients
104
Services billed
286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$117,210
JardianceEmpagliflozin64$81,419
TrulicityDulaglutide32$46,145
RybelsusSemaglutide13$37,211
Tresiba Flextouch U-100Insulin Degludec44$28,554
JanuviaSitagliptin Phosphate16$22,619
FarxigaDapagliflozin Propanediol19$22,019
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$19,141
MounjaroTirzepatide18$19,018
Tresiba Flextouch U-200Insulin Degludec11$13,205
Lantus SolostarInsulin Glargine,hum.Rec.Anlog66$10,234
Humalog Kwikpen U-100Insulin Lispro27$9,781
Novolog FlexpenInsulin Aspart13$3,711
Levothyroxine Sodium127$1,337
Droplet Pen NeedlePen Needle, Diabetic13$1,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$363$154,42191 claims
Boehringer IngelheimJardiance$22$81,41964 claims
Lilly USA, LLCTrulicity, Mounjaro$182$65,16450 claims
MerckJanuvia$55$22,61916 claims
AstraZenecaFarxiga$93$22,01919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,756 physician assistant providers in Oregon.

Other physician assistant in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →